# Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

> **NCT02407080** · PHASE1 · COMPLETED · sponsor: **John Mascarenhas** · enrollment: 13 (actual)

## Conditions studied

- Polycythemia Vera
- Essential Thrombocythemia

## Interventions

- **DRUG:** RG7388
- **DRUG:** Pegasys

## Key facts

- **NCT ID:** NCT02407080
- **Lead sponsor:** John Mascarenhas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2018-12-19
- **Final completion:** 2018-12-19
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-09-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02407080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02407080, "Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02407080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*